Immunorizon

Company Overview

Snapshot

Founded in December 2017, Immunorizon operates with 1–10 employees and was acquired by Purple Biotech in February 2023. The company had three funding rounds with investors M Ventures and ExploreBio prior to its acquisition.

Business overview

Immunorizon is a Health Tech & Life Sciences company focused on developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy. The company's core technology involves extending its pipeline with tri-specific constructs that incorporate additional tumor-associated antigens and diverse engagers for both T-cells and NK-cells. Operating within the Pharmaceuticals sector, Immunorizon serves the oncology and immunology markets with its biotechnology-driven solutions, currently with products in the clinical trial stage.

Company Intelligence Q&A

When was Immunorizon acquired?

Immunorizon was acquired by Purple Biotech in February 2023.

What is Immunorizon's primary focus in cancer therapy?

Immunorizon focuses on developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy, utilizing tri-specific constructs with additional tumor-associated antigens.

When was Immunorizon founded?

Immunorizon was founded in December 2017.

Which investor participated in Immunorizon's funding rounds?

M Ventures participated in Immunorizon's funding rounds in December 2017, April 2019, and February 2020.

What is the current product stage for Immunorizon?

Immunorizon's products are currently in the Clinical Trial stage, indicating they are undergoing testing in human subjects to evaluate their safety and efficacy.